S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.

MLA

J, Millan Mark, et al. “S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole.” The Journal of Pharmacology and Experimental Therapeutics, vol. 309, no. 3, June 2004, pp. 921–35. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=ejs6543841&authtype=sso&custid=ns315887.

APA

J, M. M., Benjamin, D. C., Michael, H., Michael, J., N, J. J., Jonathan, B., Steve, M., Alan, C., Lance, S., Peter, J., Alain, G., Jean-Louis, P., & Mauricette, B. (2004). S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. The Journal of Pharmacology and Experimental Therapeutics, 309(3), 921–935.

Chicago

J, Millan Mark, Di Cara Benjamin, Hill Michael, Jackson Michael, Joyce Jeffrey N, Brotchie Jonathan, McGuire Steve, et al. 2004. “S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole.” The Journal of Pharmacology and Experimental Therapeutics 309 (3): 921–35. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=ejs6543841&authtype=sso&custid=ns315887.